Altimmune, Inc. (ALT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 15.04 |
| Open | 14.81 |
| Bid | 15.00 x 1000 |
| Ask | 15.71 x 800 |
| Day's Range | 14.81 - 15.95 |
| 52 Week Range | 3.83 - 23.49 |
| Volume | |
| Avg. Volume | 1,484,503 |
| Market Cap | 745.252M |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 20, 2017 |
| 1y Target Est | N/A |
- GlobeNewswire
Altimmune Appoints Raymond Jordt as Chief Business Officer
Mr. Jordt brings over 25 years of industry experience in corporate strategy and business developmentGAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Mr. Jordt succeeds José Ochoa, who is leaving Altimmune to pursue other opportunities. Mr. Jordt is an accomplished executive with over 25 years of experience in the pha
- GlobeNewswire
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the results of Altimmune’s recently completed 12-week Phase 1b and 12-week extension trials of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference, which will be
- GlobeNewswire
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Greater than 75% relative reduction in liver fat content achieved at the 1.8 mg and 2.4 mg doses at 24 weeksSignificant reductions in serum alanine aminotransferase (ALT) and corrected T1 (cT1) observed, both established markers of liver inflammationMean weight loss of 7.2% (placebo adjusted 6.0%) in subjects without diabetes at the 1.8 mg doseGlycemic control maintained with trends toward improvements in fasting glucose and HbA1c in subjects with diabetesMeaningful reductions in blood pressure
